Semaglutide can help lower the risk of cardiovascular complications in people with diabetes, a new study has found.

A new sub-analysis of the SELECT trial data shows semaglutide 2.4 mg substantially reduces the burden of total cardiovascular ...

Three months of dual antiplatelet therapy after PCI may safely balance thrombosis and bleeding risk in both patients with low ...

The first clinical guidance for cardiogenic shock will be presented at the American College of Cardiology Scientific Session ...

Aims Cardiovascular (CV) deaths were reduced by atorvastatin during a 16-year follow-up of participants in the ...

If that were the case, a non-STEMI or unstable angina may be present, as the changes are indeed from myocardial ischemia, but not officially a STEMI — meaning a big time difference in regards to ...

Novo Nordisk has submitted a supplemental application to the FDA for Rybelsus 14 mg to lower cardiovascular risk in adults ...

BAGSVAERD, Denmark I March 29, 2025 I Novo Nordisk today presented the full results from the SOUL cardiovascular outcomes trial, demonstrating that Rybelsus® ...

AstraZeneca’s IMFINZI® (durvalumab) in combination with gemcitabine and cisplatin as neoadjuvant treatment, followed by IMFINZI as adjuvant monotherapy after radical cystectomy (surgery to remove the ...

Innodata sees explosive growth with LLM training data demand. See why INOD stock’s future depends on automation and continued ...